JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275
Loading...